 SAN DIEGO, Oct. 01, 2021 GLOBE NEWSWIRE -- Fate Therapeutics, Inc. NASDAQ: FATE, a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that one oral and four poster presentations for the Companys induced pluripotent stem cell iPSC product platform were accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer SITC being held November 10-14, 2021. 